Cargando…
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI). However, recurrence events still remain, which may be partly due to inadequate platelet inhibition...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369137/ https://www.ncbi.nlm.nih.gov/pubmed/28335443 http://dx.doi.org/10.3390/ijerph14030301 |
_version_ | 1782518071282368512 |
---|---|
author | Zhang, Yan-Jiao Li, Mu-Peng Tang, Jie Chen, Xiao-Ping |
author_facet | Zhang, Yan-Jiao Li, Mu-Peng Tang, Jie Chen, Xiao-Ping |
author_sort | Zhang, Yan-Jiao |
collection | PubMed |
description | Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI). However, recurrence events still remain, which may be partly due to inadequate platelet inhibition by standard clopidogrel therapy. Genetic polymorphisms involved in clopidogrel’s absorption, metabolism, and the P2Y12 receptor may interfere with its antiplatelet activity. Recent evidence indicated that epigenetic modification may also affect clopidogrel response. In addition, non-genetic factors such as demographics, disease complications, and drug-drug interactions can impair the antiplatelet effect of clopidogrel. The identification of factors contributing to the variation in clopidogrel response is needed to improve platelet inhibition and to reduce risk for cardiovascular events. This review encompasses the most recent updates on factors influencing pharmacokinetic and pharmacodynamic responses to clopidogrel. |
format | Online Article Text |
id | pubmed-5369137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53691372017-04-05 Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives Zhang, Yan-Jiao Li, Mu-Peng Tang, Jie Chen, Xiao-Ping Int J Environ Res Public Health Review Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI). However, recurrence events still remain, which may be partly due to inadequate platelet inhibition by standard clopidogrel therapy. Genetic polymorphisms involved in clopidogrel’s absorption, metabolism, and the P2Y12 receptor may interfere with its antiplatelet activity. Recent evidence indicated that epigenetic modification may also affect clopidogrel response. In addition, non-genetic factors such as demographics, disease complications, and drug-drug interactions can impair the antiplatelet effect of clopidogrel. The identification of factors contributing to the variation in clopidogrel response is needed to improve platelet inhibition and to reduce risk for cardiovascular events. This review encompasses the most recent updates on factors influencing pharmacokinetic and pharmacodynamic responses to clopidogrel. MDPI 2017-03-14 2017-03 /pmc/articles/PMC5369137/ /pubmed/28335443 http://dx.doi.org/10.3390/ijerph14030301 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhang, Yan-Jiao Li, Mu-Peng Tang, Jie Chen, Xiao-Ping Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title_full | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title_fullStr | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title_full_unstemmed | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title_short | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
title_sort | pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369137/ https://www.ncbi.nlm.nih.gov/pubmed/28335443 http://dx.doi.org/10.3390/ijerph14030301 |
work_keys_str_mv | AT zhangyanjiao pharmacokineticandpharmacodynamicresponsestoclopidogrelevidencesandperspectives AT limupeng pharmacokineticandpharmacodynamicresponsestoclopidogrelevidencesandperspectives AT tangjie pharmacokineticandpharmacodynamicresponsestoclopidogrelevidencesandperspectives AT chenxiaoping pharmacokineticandpharmacodynamicresponsestoclopidogrelevidencesandperspectives |